Eni SpA vs Koninklijke Philips NV — how do they compare? Eni SpA trades at $48.31 (market cap $70.34B), while Koninklijke Philips NV trades at $27.23 (market cap $26.29B). The key difference: Eni SpA is far larger — about 2.7× Koninklijke Philips NV's market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.
| E | PHG | |
|---|---|---|
Market Cap | $70.34B | $26.29B |
Sector | Energy | Health |
52-Week High | $57.61 | $32.91 |
52-Week Low | $32.93 | $24.38 |
Enterprise Value | $89.25B | $32.56B |
Dividend Yield | 4.99% | 3.75% |
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
Royal Philips (PHG) trades at $26.06, down 4.68% today, with bearish technical signals but improving fundamentals. The company reported strong Q1 2026 earnings beat and maintains a 5.5% net income margin. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight innovation momentum. Cash flow remains positive at $403M for 2025, though debt-to-asset ratio increased to 25.44%.
PHG shows recovery potential with earnings growth and AI healthcare adoption, but faces execution risks and technical weakness. Analyst consensus leans Hold (59%) with no Sell ratings, suggesting cautious optimism. Key risks include competitive pressures and macroeconomic volatility affecting medical equipment demand.
Trailing returns across standard periods
Latest headlines on both assets
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →